论文部分内容阅读
目的评估重组溶葡萄球菌素对烧伤创面分离的金黄色葡萄球菌的体外抗菌活性。方法收集烧伤创面分离的金黄色葡萄球菌共171株。采用琼脂稀释法测定临床烧伤常用药物万古霉素、红霉素、克林霉素、头孢西丁及磺胺甲噁唑对金黄色葡萄球菌的最低抑菌浓度(MIC);根据头孢西丁的MIC值区分耐甲氧西林的金黄色葡萄球菌(MRSA)和甲氧西林敏感的金黄色葡萄球菌(MSSA);根据万古霉素、红霉素、克林霉素、磺胺甲噁唑的药物敏感试验结果对金黄色葡萄球菌进行耐药性分析。采用微量肉汤稀释法检测重组溶葡萄球菌素对金黄色葡萄球菌的MIC,计算50%最低抑菌浓度(MIC50)和90%最低抑菌浓度(MIC90)。结果根据药物敏感试验结果,收集的171株金黄色葡萄球菌对磺胺甲噁唑、红霉素、克林霉素和万古霉素的耐药率分别为99.4%、88.3%、87.1%和0,其中MRSA有146株(占85.4%)。重组溶葡萄球菌素对金黄色葡萄球菌的MIC范围为0.015～0.5 U/mL,MIC50为<0.015 U/mL,MIC90为0.03 U/mL。结论重组溶葡萄球菌素对金黄色葡萄球菌具有较好的体外抗菌活性。在金黄色葡萄球菌耐药性日益增强的情况下,对于临床烧伤创面感染的预防和治疗,重组溶葡萄球菌素是一种极具开发潜力的新药。
Objective To evaluate the in vitro antibacterial activity of recombinant lysostaphin on Staphylococcus aureus isolated from burn wounds. Methods A total of 171 strains of Staphylococcus aureus isolated from burn wounds were collected. The minimal inhibitory concentrations (MICs) of vancomycin, erythromycin, clindamycin, cefoxitin and sulfamethoxazole on Staphylococcus aureus were determined by agar dilution method. According to MIC of cefoxitin Values discriminated methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible Staphylococcus aureus (MSSA); drug susceptibility tests based on vancomycin, erythromycin, clindamycin, sulfamethoxazole Results The drug resistance of Staphylococcus aureus was analyzed. MICs of recombinant lysostaphin against Staphylococcus aureus were assayed by the broth microdilution method, and the minimum inhibitory concentration (MIC50) and the minimum inhibitory concentration (MIC90) of 50% were calculated. Results According to the results of drug susceptibility test, the susceptibilities of 171 strains of Staphylococcus aureus to sulfamethoxazole, erythromycin, clindamycin and vancomycin were 99.4%, 88.3%, 87.1% and 0, respectively, There were 146 strains of MRSA (accounting for 85.4%). The MICs of recombinant lysostaphin against Staphylococcus aureus were 0.015-0.5 U / mL, MIC50 was <0.015 U / mL and MIC90 was 0.03 U / mL. Conclusion Recombinant lysostaphin has good antibacterial activity against Staphylococcus aureus in vitro. With the increasing resistance of Staphylococcus aureus, recombinant Lysostaphin is a promising new drug for the prevention and treatment of wound infection in clinical burn wounds.